Arterial hypertension and COVID-19 infections: A brief commentary
Authors:
Jiří Widimský
Authors‘ workplace:
Centrum pro hypertenzi, III. interní klinika VFN a 1. LF UK Praha
Published in:
Vnitř Lék 2020; 66(3): 104-106
Category:
Overview
The issue of hypertension/antihypertensive treatment in patients with COVID-19 infection is discussed in the commentary.
Keywords:
hypertension – COVID-19 – Antihypertensive drugs
Sources
1. Danser J, Epstein M, Batlle Renin -Angiotensin D. System Blockers and the COVID-19 Pandemic At Present There Is No Evidence to Abandon Renin -Angiotensin System Blockers. Hypertension June 2020/ DOI: 10.1161/HYPERTENSIONAHA.120.15082.
2. Esler M, Esler D. Can angiotensin receptor -blocking drug perhaps be harmful in the COVID-19 pandemic? J Hypertension, 2020, 38, 781–782.
3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V and Desormais I. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of hypertension. 2018; 36 : 1953–2041.
4. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2017. Doporučení České společnosti pro hypertenzi J. Widimský jr., J. Filipovský, J. Ceral, R. Cífková, A. Linhart, V. Monhart, H. Rosolová, J. Seidlerová Mlíková, M. Souček, J. Špinar, V.Tesař, J. Vítovec T. Zelinka. Hypertenze a kardiovaskulární prevence, 2018, supplement, str. 1–22.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2020 Issue 3
-
All articles in this issue
- „All‑in‑one“ concept of functional myocardial revascularization in the cathlab
- Long term antithrombotic threapy after myocardial infarction: why, to whom and which one?
- Are proton pump inhibitors an effective and safe drug not only in the prophylaxis of gastrointestinal bleeding in antithrombotic treatment?
- Psychical reaction of patients to the negative information on cancer diagnosis
- What is hiden behind autoinflammation?
- Cardiac involvement in hypereosinophilia
- Importance of breath tests for the evaluation liver function in patients with chronic kidney disease
- Adherence to cardiovascular prevention principles in subjects at high risk
- The first cases of genetically confirmed congenital diarrhea with chloride loss in Slovakia
- Stress kardiomyopathy triggered by unusual situation
- Hepatorenal syndrome – update 2020
- Local thrombolysis for deep vein thrombosis: why, for whom and how?
- What are the blood pressure targets for patients with chronic kidney disease?
- Proteinuria from an internist‘s point of view
- Proteinuria from an internist‘s point of view
- Euvascor – early intervention of hypertension and dyslipidaemia (dual combination of atorvastatin and perindopril)
- Rivaroxaban in COMPASS trial
- Arterial hypertension and COVID-19 infections: A brief commentary
- Vnitřní lékařství v době koronavirové
- Vážení a milí čtenáři Vnitřního lékařství,
- Miroslav Souček, Petr Svačina a kolektiv. Vnitřní lékařství v kostce. Grada; Praha 2019; 462 stran; ISBN 978-80-271-2289-9 (print)
- Profesorka MUDr. Sylvie Opatrná, PhD. – in memoriam (1959–2020)
- Distant diabetes care: what can the patient, nurse and patient do
- Internal Medicine
- Journal archive
- Current issue
- Online only
- About the journal
Most read in this issue
- What is hiden behind autoinflammation?
- Local thrombolysis for deep vein thrombosis: why, for whom and how?
- Proteinuria from an internist‘s point of view
- Hepatorenal syndrome – update 2020